Holen Sie sich die Stockscreener-App
11.24
10.51%
-1.32
Polyrizon Ltd Aktie (PLRZ) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon (PLRZ) Latest: Closes 6.26% Lower at $10.49 in the Current Update; Range Check: Support at $9.97 and Resistance at $11.01 Frame the Range in Latest TradingWyckoff Accumulation - vinanet.vn
Polyrizon Finalizes U.S. Clinical Site Network for NASARIX Allergy Study - TipRanks
Polyrizon (PLRZ) lines up sites for 120-patient allergy study - Stock Titan
Polyrizon completes contracting with all five clinical sites By Investing.com - Investing.com South Africa
Polyrizon Completes Site Contracting for NASARIX™ Seasonal Allergic Rhinitis Study - Quiver Quantitative
Polyrizon's planned allergy study will compare its spray with saline in up to 120 patients - Stock Titan
Polyrizon (PLRZ) Close and Levels: Records a 5.65% Decrease to $10.36 for the Current Session; Nearby Levels: the Current Price Sits Inside the Supplied Technical Range in the Available RecordRectangle Pattern - vinanet.vn
Polyrizon Ltd. (PLRZ) Gains 2.14% to $10.98, Holding Support Amid Biotech InterestTPO Profile - vinanet.vn
Polyrizon Ltd. (PLRZ): MMCAP group discloses 9.6% beneficial stake - Stock Titan
DISCLOSED: Insiders Are Now Buying *This Stock* Sootoday.com (Je9ZHM0WVP) - Mshale
Polyrizon Ltd (PLRZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polyrizon Ltd. (PLRZ) Slips 2.24% as Shares Test Key Support Zone Near $10.76Up Down Volume - dars.gov.et
PLRZ.O PE Ratio & Valuation, Is PLRZ.O Overvalued - Intellectia AI
Polyrizon Ltd (PLRZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Polyrizon Ltd (PLRZ) Institutional Confidence - TradingKey
Polyrizon Ltd (PLRZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Polyrizon Ltd (PLRZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Polyrizon Ltd (PLRZ) Cash Flow - TradingKey
Polyrizon Ltd (PLRZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Polyrizon Ltd (PLRZ) Balance Sheet - TradingKey
TradingKey - TradingKey
Polyrizon Ltd (PLRZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Polyrizon Ltd. Revenue Breakdown – NASDAQ:PLRZ - TradingView
PLRZ|Polyrizon Ltd|Price:13.800|Chg%:-0.880 - TradingKey
Polyrizon (PLRZ) Advances 3.23% as Stock Tests Key Resistance Near $14.09Volume Nodes - dars.gov.et
Polyrizon (PLRZ) Slips Slightly as Stock Hovers Near Support LevelsFibonacci Time Zone - vinanet.vn
Polyrizon Shareholders Approve New Executive Compensation Policy on July 13, 2026 - TipRanks
Polyrizon (PLRZ) locks in 3-year executive and director pay policy - Stock Titan
Polyrizon Ltd. (PLRZ) Rises 2.09% as Shares Approach Resistance at $15.38Buyback Factor - dars.gov.et
Polyrizon Ltd. (PLRZ) Rallies 7.32% to $15.40 — Bulls Test Key ResistanceDouble Top - DonanımHaber
Polyrizon (PLRZ) Holds Steady Near Support as Stock Edges HigherOption Strike Build - dars.gov.et
Polyrizon retains Nasdaq listing following hearings panel - MSN
Polyrizon Clears Key Safety Milestone for NASARIX Allergy Nasal Spray - TipRanks
Polyrizon (PLRZ) clears NASARIX biocompatibility milestone toward first human trial - Stock Titan
Polyrizon Advances on Test Results - Baystreet.ca
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ) - Yahoo Finance
Polyrizon completes biocompatibility tests for allergy nasal spray - Investing.com
Polyrizon stock rises on biocompatibility test results By Investing.com - Investing.com Nigeria
Polyrizon completes biocompatibility tests for allergy nasal spray By Investing.com - Investing.com Canada
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial - The Manila Times
Polyrizon Announces Successful Biocompatibility Results for NASARIX Allergy Blocker Nasal Spray - Quiver Quantitative
Polyrizon’s allergy nasal spray clears safety tests, advancing human trial plans - Stock Titan
Polyrizon stock rises on biocompatibility test results - Investing.com
Polyrizon Wins Central IRB Nod for First NASARIX Allergy Blocker Trial - TipRanks
[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC FilingForm 6-K - Stock Titan
Polyrizon receives IRB approval for nasal spray clinical trial By Investing.com - Investing.com Nigeria
Polyrizon receives IRB approval for nasal spray clinical trial - Investing.com
Polyrizon Receives Central IRB Approval for First Human Clinical Trial of NASARIX Allergy Blocker - Quiver Quantitative
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial - The Manila Times
Polyrizon clears review to start first NASARIX human allergy trial - Stock Titan
Polyrizon (PLRZ) Modestly Gains, Testing Key Resistance ZoneWyckoff Accumulation - dars.gov.et
Enterprise value to EBIT forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Enterprise value to revenue forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Enterprise value to EBITDA forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Price to sales forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):